Finance
Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, endpoints news reports
Published by Global Banking & Finance Review®
Posted on March 3, 2026
2 min readLast updated: March 3, 2026
Quick Summary
Hims & Hers’ compounding partner, Strive Pharmacy, intends to reintroduce its compounded GLP‑1 weight‑loss pill via other healthcare providers after halting sales due to regulatory scrutiny; no timeline yet, pending how the situation develops, per Endpoints News.
Strive Pharmacy to Reintroduce Hims' Compounded GLP-1 Pill Amid Regulatory Review
Strive Pharmacy's Plans and Industry Response
Background and Recent Developments
March 3 (Reuters) - Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. regulatory pushback, Endpoints News reported on Tuesday.
Timeline for Reintroduction
Arizona-based Strive has not decided on a timeline yet but will wait to see how "everything settles out before we reintroduce it," the report said, citing an interview with the management of the compounding pharmacy behind Hims' pill.
Compounded Semaglutide Pill Offering
Hims' Announcement and Pricing
Last month, Hims announced plans to offer a compounded oral semaglutide pill for $49, a version of Novo Nordisk's new Wegovy pill launched just a month earlier.
Regulatory and Industry Backlash
FDA and Novo Nordisk Response
The risky move was quick to earn backlash from Novo and the U.S. Food and Drug Administration, which referred the company to the Department of Justice and threatened to restrict the ingredients that pharmacies mix to make their compounded versions.
Market Impact
Novo Nordisk's Denmark-listed shares were down nearly 2%, while rival Eli Lilly was down 1.7% after the report on Tuesday.
Statements and Comments
Company Responses
Strive and Novo did not immediately respond to Reuters' requests for comment.
Reporting Credits
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Key Takeaways
- •Strive Pharmacy plans to resume sales of its compounded GLP‑1 (semaglutide) pill through other providers after pulling it amid FDA and DOJ scrutiny (cnbc.com).
- •The FDA ended its shortage exemption for compounded semaglutide and tirzepatide in early to mid‑2025, making general compounding illegal, although tailored prescriptions remain allowed (glp-1.com).
- •Strive has faced regulatory challenges—including a 2024 consent agreement and a 2025 inspection finding compounding past the shortage period—but disputes those findings (sherwood.news).
References
Frequently Asked Questions about Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports
1Why did Strive Pharmacy halt sales of the compounded GLP-1 pill?
Strive Pharmacy paused distribution following regulatory pushback from the FDA, which cited safety and ingredient concerns.
2What is the compounded GLP-1 pill related to Hims & Hers Health?
It is an oral semaglutide pill, a compounded version of Novo Nordisk's Wegovy weight-loss pill, offered at $49.
3When will Strive Pharmacy reintroduce the compounded GLP-1 pill?
Strive Pharmacy has not set a timeline and will wait for regulatory clarity before reintroducing the pill.
4How did the market react to news about Strive Pharmacy's plans?
Novo Nordisk and Eli Lilly shares both dropped following the report on plans to resume the compounded GLP-1 pill sales.
5What actions has the FDA taken regarding compounded weight-loss pills?
The FDA referred the pharmacy to the Department of Justice and threatened ingredient restrictions for such compounded versions.
